Lockton Risk Finance

— RISK MANAGEMENT

Risk Finance

Superior results happen when you treat insurance as a form of capital.

Delivering results

Nowhere else will you find a team dedicated solely to solving your risk financing and collateral issues. Lockton’s Risk Finance team meets our clients' ever-increasing demand for risk alternatives through captive consultation, collateral management strategies, and alternative structure solutions.

The team is a collaborative group of finance, accounting, credit, and insurance professionals whose primary role is to assist our service teams with the design and implementation of program structures that match our clients' needs from a cost-of-risk, cash-flow, accounting, tax and collateral perspective. This group is renowned for delivering results while linking clients' risk management programs to their strategic and financial objectives.

The Lockton Risk Finance difference

You will have experts working seamlessly with our marketing and quantitative analysis teams to deliver integrated risk financing solutions. Services the team offers include:

  • Provide risk finance solutions to manage client balance sheet and cash flow volatility

  • Consult on effective captive insurance strategies

  • Evaluate and construct bespoke alternative program structures to meet the client’s needs

  • Evaluate the most efficient use of client’s capital

  • Compare insurance costs against a client's cost of capital

  • Navigate through carrier credit underwriting process

  • Eliminate redundant working capital

  • Help clients make informed decisions

  • Provide ongoing consultation — going beyond transactional insurance services

Latest news & insights

Employers with group health plans that provide prescription drug coverage to Medicare-eligible individuals must submit an annual disclosure to the Centers for Medicare & Medicaid Services (CMS) whether their coverage is “creditable” or “non-creditable” (i.e., whether the actuarial value equals or exceeds the actuarial value of defined standard Part D coverage). Medicare Part-D creditable/non-creditable coverage disclosure to CMS due March 2, 2025

Medicare Part-D creditable/non-creditable coverage disclosure to CMS due March 2, 2025

article
Employers with group health plans that provide prescription drug coverage to Medicare-eligible individuals must submit an annual disclosure to the Centers for Medicare & Medicaid Services (CMS) whether their coverage is “creditable” or “non-creditable” (i.e., ...
Read moreMedicare Part-D creditable/non-creditable coverage disclosure to CMS due March 2, 2025

Ransomware hits the educator sector: lessons learned for schools and risk professionals

Here’s what schools should know about the recent cyber incident, how they can respond to it, and how they can prepare for the next potential cyber eventHere’s what schools should know about the recent cyber incident, how they can respond to it, and how they can prepare for the next potential cyber event

Lockton appoints Mark Jones as International Chief Financial Officer

Lockton, the world’s largest independent insurance broker, has appointed Mark Jones as its new International Chief Financial Officer (CFO), effective immediately. Lockton, the world’s largest independent insurance broker, has appointed Mark Jones as its new International Chief Financial Officer (CFO), effective immediately.

Life Sciences: Cyber and SEC Requirements

In fiscal year 2024, the SEC settled charges against more than two dozen entities/individuals for failing to report cybersecurity incidents, imposing fines of up to $4 million. These strict reporting rules and tight deadlines are particularly challenging for smaller publicly-traded Life Science companies that may lack the internal resources to effectively meet these demands. Read our latest thought leadership on how Lockton can help.In fiscal year 2024, the SEC settled charges against more than two dozen entities/individuals for failing to report cybersecurity incidents, imposing fines of up to $4 million. These strict reporting rules and tight deadlines are particularly challenging for smaller publicly-traded Life Science companies that may lack the internal resources to effectively meet these demands. Read our latest thought leadership on how Lockton can help.
View All news and insights